Head-to-head evidence
CX11 vs DA-302168S
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CX11
Developed by Corxel Pharmaceuticals
NCT07011797 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled Phase 2 trial, 250 adults with obesity were assigned to CX11 at several doses or placebo for 26 weeks, with follow-up to 36 weeks. The company reported that the trial's weight-loss primary endpoints were met, with weight loss reaching up to 11.5% by week 36 and continuing without a plateau; gastrointestinal side effects were the most common safety finding.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT07652047 (registry estimate)
DA-302168S
Developed by Chendu DIAO Pharmaceutical Group
NCT06953063 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 250 participants, with percentage change in body weight as a clinical primary endpoint. However, results are not posted, so it is not possible to determine whether the primary comparison was met; the available evidence therefore supports a moderate grade rather than a strong one.
Next expected readout: July 2027 · NCT07629544 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CX11's landscape · DA-302168S's landscape